Trillium Therapeutics Inc (TRIL)

[NY1972]

Epacadostat plus pembrolizumab in patients with advanced melanoma and select solid tumors: Updated phase 1 results from ECHO-202/KEYNOTE-037

pts previously treated with checkpoint inhibitors were excluded.

Among 19 pts who were treatment-naive for advanced melanoma (M1c 53%), 4 CRs, 7 PRs, and 3 SDs were observed. Responses were observed in all epac dose cohorts ≥50 mg BID and all sites of target lesions including liver, lung, and lymph nodes. All responses are confirmed and ongoing (median follow-up [min, max]: 42 wks [31.7, 75.9]). Median PFS has not been reached. Responses were also observed in pts previously treated for advanced melanoma (n = 3; 1 CR, 1 SD) and pts with NSCLC (n = 12; 5 PRs, 2 SDs), RCC (n = 11; 3 PRs, 5 SDs), endometrial adenocarcinoma (n = 7; 1 CR, 1 PR), TCC (n = 5; 3 PRs), TNBC (n = 3; 2 SDs), SCCHN (n = 2; 1 PR, 1 SD).

https://cslide.ctimeetingtech.com/library/esmo/browse/search/CCe#2z9580Ho